CDRC60201-Millipore密理博RO膜

  • 型号 CDRC60201
  • 品牌 Merck Millipore密理博
  • 【简单介绍】
    品牌 其他品牌

    Millipore密理博RO膜
    说明: 用于 Elix 5,RiOs 8和AFS 8 系统的 RO 膜
    商标名: Milli-RO
    数量/包装: 1
    产品名称: RO 膜

    说明: 用于 Elix 5,RiOs 8和AFS 8 系统的 RO 膜

     商标名: Milli-RO 

     数量/包装: 1

     产品名称: RO 膜

    Millipore密理博RO膜 CDRC60201

    MERCK MILLIPORE 默克密理博RiOs 5/8/16 水纯化系统介绍

    直接生产 III 级实验室用水,产水流速可达 16L/hRiOs 系统以稳定的流速产生 III 级实验室用纯水 系统直接使用自来水做进水,将辅助纯化技术结合在一个紧凑的系统设计中,不仅操作方便、可靠,还允许以低操作成本对产水水质进行全面控制。

Ginsenoside Ro(Synonyms: 人参皂苷 Ro; Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V)

天然产物 糖类和糖苷 Saccharides and Glycosides

Ginsenoside Ro (Synonyms: 人参皂苷 Ro; Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) 纯度: 99.21%

Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) 具有 Ca2+ 拮抗剂的抗血小板作用,IC50 为 155  μM。Ginsenoside Ro 降低 TXA2 产量,Ginsenoside Ro 还稍弱地降低 COX-1 和 TXAS 活性。

Ginsenoside Ro(Synonyms: 人参皂苷 Ro; Polysciasaponin P3;  Chikusetsusaponin 5;  Chikusetsusaponin V)

Ginsenoside Ro Chemical Structure

CAS No. : 34367-04-9

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥1470 In-stock
5 mg ¥800 In-stock
10 mg ¥1400 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Ginsenoside Ro 相关产品

相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • GPCR/G Protein Compound Library
  • Immunology/Inflammation Compound Library
  • Membrane Transporter/Ion Channel Compound Library
  • Neuronal Signaling Compound Library
  • Natural Product Library
  • Anti-Aging Compound Library
  • Glycoside Compound Library
  • Oxygen Sensing Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Endocrinology Compound Library
  • Medicine Food Homology Compound Library
  • Terpenoids Library
  • Traditional Chinese Medicine Monomer Library
  • FDA Approved & Pharmacopeial Drug Library
  • Neuroprotective Compound Library
  • Angiogenesis Related Compound Library
  • Food-Sourced Compound Library
  • Targeted Diversity Library

生物活性

Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a Ca2+-antagonistic antiplatelet effect with an IC50 of 155  μM. Ginsenoside Ro reduces the production of TXA2 more than it reduces the activities of COX-1 and TXAS.

IC50 & Target[1][2]

TXA2

 

Ca2+

 

体外研究
(In Vitro)

Ginsenoside Ro in Panax ginseng is a beneficial novel Ca2+-antagonistic compound and may prevent platelet aggregation-mediated thrombotic disease. Ginsenoside Ro dose-dependently reduces thrombin-stimulated platelet aggregation, and IC50 is approximately 155 μM[1]. Ginsenoside Ro inhibits TXA2 production to abolish thrombin-induced platelet aggregation. Thromboxane A2 (TXA2) induces platelet aggregation and promotes thrombus formation. Ginsenoside Ro dose-dependently (50-300 μM) reduces the TXB2 level that is induced by thrombin; Ginsenoside Ro (300 μM) inhibits the thrombin-mediated elevation in TXB2 level by 94.9%. COX-1 activity in the absence of Ginsenoside Ro (negative control) is 2.3±0.1 nmol/mg protein. However, Ginsenoside Ro dose-dependently (50-300 μM) reduces its activity; at 300 μM, COX-1 activity is reduced by 26.4% of that of the negative control. TXA2 synthase (TXAS) activity in the absence of Ginsenoside Ro (negative control) is 220.8±1.8 ng/mg protein/min. However, Ginsenoside Ro dose-dependently (50-300 μM) reduces its activity; at 300 μM, TXAS activity is reduced by 22.9% of that of the negative control. The inhibitory effect of Ginsenoside Ro (300 μM) on TXB2 production (94.9%) is significantly higher than those on COX-1 (26.4%) and TXAS (22.9%) activities[2]. To assess the toxicity of Ginsenoside Ro in Raw 264.7 cells, they are first treated with various concentrations (10 μM, 50 μM, 100 μM, and 200 μM) of Ginsenoside Ro for 24 h. Ginsenoside Ro exhibits no significant dose dependent toxicity. The effect of Ginsenoside Ro is next determined on cell viability and ROS levels, a marker of oxidative stress, following treatment with 1 μg/mL LPS. LPS reduces cell viability by ∼70% compared with nontreated controls. Pretreatment with 100 μM and 200 μM Ginsenoside Ro for 1 h prior to 1 μg/mL LPS incubation for 24 h leads to a significant increase in cell viability. The changes in ROS levels and NO production are consistent with the effects of Ginsenoside Ro on viability[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Ginsenoside Ro dissolved in water is administrated by gavage to mice at doses of 25 and 250 mg/kg/day for 4 days before i.v. injection of HT29 in order to keep blood concentrations of Ginsenoside Ro above a certain level before HT29 i.v. injection followed by 40 days of oral administration of Ginsenoside Ro to the mice. After 38 days of treatment, the animals are euthanized, and the number of pulmonary metastatic nodules is counted in addition to evaluation of toxicity of Ginsenoside Ro and mouse pathology by HT29. Ginsenoside Ro (250 mg/kg/day) produces a significant decrease in the number of tumor nodules on the lung surface, yielding inhibition rates of 88% (P < 0.01)[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

957.11

Formula

C48H76O19

CAS 号

34367-04-9

中文名称

人参皂苷 Ro;人参皂苷 Ro

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (104.48 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.0448 mL 5.2241 mL 10.4481 mL
5 mM 0.2090 mL 1.0448 mL 2.0896 mL
10 mM 0.1045 mL 0.5224 mL 1.0448 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (2.61 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.61 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (2.61 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.61 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.61 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.61 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Kwon HW, et al. Inhibitory Effects of Cytosolic Ca2+ Concentration by Ginsenoside Ro Are Dependent on Phosphorylation of IP3RI and Dephosphorylation of ERK in Human Platelets. Evid Based Complement Alternat Med. 2015;2015:764906.

    [2]. Jung-HaeShin, et al. Inhibitory effects of thromboxane A2 generation by ginsenoside Ro due to attenuation of cytosolic phospholipase A2 phosphorylation and arachidonic acid release. J Ginseng Res. 9 Jan 2018.

    [3]. Kim S, et al. Upregulation of heme oxygenase-1 by ginsenoside Ro attenuates lipopolysaccharide-induced inflammation in macrophage cells. J Ginseng Res. 2015 Oct;39(4):365-70.

    [4]. Jiang Z, et al. The traditional Chinese medicine Achyranthes bidentata and our de novo conception of its metastatic chemoprevention: from phytochemistry to pharmacology. Sci Rep. 2017 Jun 20;7(1):3888.

Kinase Assay
[2]

The microsomal fraction of platelets is preincubated with Ozagrel (11 nM, IC50), a positive control, or with various concentrations of Ginsenoside Ro and other reagents at 37°C for 5 min. The reaction is initiated by adding prostaglandin H2, and the samples are incubated at 37°C for 1 min; the reaction is terminated by adding citric acid (1 M). After neutralization with 1 N NaOH, the amount of TXB2 is determined using a TXB2 EIA kit[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay
[3]

Cell viability is determined with an MTT assay kit. Briefly, Raw 264.7 cells are plated in 48-well plates at a density of 2.0×104 cells per well, incubated for 24 h, and treated with various concentrations of Ginsenoside Ro for 24 h. How 1 h of pretreatment with Ginsenoside Ro (50 μM, 100 μM, and 200 μM) affects the viability of Raw 264.7 cells is then investigated treated with 1 μg/mL LPS for 24 h. After the incubation period, 10 μL of MTT reagent is added to each well and incubated for 3 h at 37°C in 5% CO2. The resulting formazan crystals are subsequently dissolved in MTT solubilization solution. The absorbance is determined at 540 nm using a microplate reader[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[4]

Mice[4]
Female BALB/c mice (20-25 g, 6-8 weeks old) are used. The experimental model of lung metastasis is established by tail vein injection of HT29 cells to mimic the dissemination of CTCs. HT29 cells in the number of 2×106 cells in 0.2 mL PBS are infected into the tail vein of six-week-old female Balb/c mice. Before the HT29 inoculation, oral gavage pretreatment of PBS-suspended B (Ginsenoside Ro) is given daily for 4 days, followed by a 40-day treatment. Treatment groups (N = 10) include: 0 mg/kg, 25 mg/kg and 250 mg/kg Ginsenoside Ro. Body weight is measured and recorded every four days. Mice are sacrificed after 40 days of tumor metastasis and growth and 44 days of treatment with B. The number of surface lung metastasis nodules is evaluated in each treatment group. Slides with 4-5 μm thick lung section are prepared, paraffin embedded and then stained with hematoxylin and eosin[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Kwon HW, et al. Inhibitory Effects of Cytosolic Ca2+ Concentration by Ginsenoside Ro Are Dependent on Phosphorylation of IP3RI and Dephosphorylation of ERK in Human Platelets. Evid Based Complement Alternat Med. 2015;2015:764906.

    [2]. Jung-HaeShin, et al. Inhibitory effects of thromboxane A2 generation by ginsenoside Ro due to attenuation of cytosolic phospholipase A2 phosphorylation and arachidonic acid release. J Ginseng Res. 9 Jan 2018.

    [3]. Kim S, et al. Upregulation of heme oxygenase-1 by ginsenoside Ro attenuates lipopolysaccharide-induced inflammation in macrophage cells. J Ginseng Res. 2015 Oct;39(4):365-70.

    [4]. Jiang Z, et al. The traditional Chinese medicine Achyranthes bidentata and our de novo conception of its metastatic chemoprevention: from phytochemistry to pharmacology. Sci Rep. 2017 Jun 20;7(1):3888.

RO27-3225 TFA

RO27-3225 TFA; 纯度: 99.57%

RO27-3225 TFA 是一种有效的选择性黑皮质素 4 受体 (MC4R) 激动剂,对于 MC4R 和 MC1R 的 EC50 分别为 1 nM 和 8 nM。RO27-3225 TFA 对 MC4R 的选择性是 MC3R 的 30 倍左右。RO27-3225 TFA 具有神经保护和抗炎作用。

RO27-3225 TFAamp;;

RO27-3225 TFA Chemical Structure

规格 价格 是否有货 数量
10;mM;*;1 mL in DMSO ¥4750 In-stock
5 mg ¥3000 In-stock
10 mg ¥4800 In-stock
50 mg ¥13500 In-stock
100 mg ; 询价 ;
200 mg ; 询价 ;

* Please select Quantity before adding items.

RO27-3225 TFA 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • GPCR/G Protein Compound Library
  • Immunology/Inflammation Compound Library
  • Neuronal Signaling Compound Library
  • Neuroprotective Compound Library
  • Anti-Obesity Compound Library
  • Peptide Library

生物活性

RO27-3225 TFA is potent and selective melanocortin 4 receptor (MC4R) agonist with an EC50 of 1 nM and 8 nM for MC4R and MC1R, respectively. RO27-3225 TFA shows ~30-fold selectivity for MC4R over MC3R. RO27-3225 TFA has neuroprotective and anti-inflammatory effects[1][2][3].

IC50 Target

EC50: 1 nM (Melanocortin 4 receptor (MC4R)), 8 nM (MC1R), 675 nM (MC3R) and 5779 nM (MC5R)[1]

体内研究
(In Vivo)

RO27-3225 (0.012-0.048 mg/kg; intravenous injection; Wistar rats) treatment reverses haemorrhagic shock, reduces multiple organ damage and improves survival. RO27-3225 could have a protective role against multiple organ failure following circulatory shock[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wistar rats of both sexes (270-300 g) with haemorrhagic shock[2]
Dosage: 0.012 mg/kg, 0.024 mg/kg, 0.048 mg/kg
Administration: Intravenous injection
Result: Reversed haemorrhagic shock, reduced multiple organ damage and improved survival.

分子量

898.93

Formula

C41H53F3N12O8

Sequence

Oxobutyl-His-Phe-Arg-Trp-{Sar}-NH2

Sequence Shortening

Oxobutyl-HFRW-{Sar}-NH2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture and light

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture and light)

溶解性数据
In Vitro:;

H2O : 100 mg/mL (111.24 mM; Need ultrasonic)

DMSO : 100 mg/mL (111.24 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.1124 mL 5.5622 mL 11.1243 mL
5 mM 0.2225 mL 1.1124 mL 2.2249 mL
10 mM 0.1112 mL 0.5562 mL 1.1124 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂:;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.5 mg/mL (2.78 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.78 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂:;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (2.78 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.78 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂:;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.78 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.78 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Benoit SC, et al. A novel selective melanocortin-4 receptor agonist reduces food intake in rats and mice without producing aversive consequences. J Neurosci. 2000 May 1;20(9):3442-8.

    [2]. Giuliani D, et al. Selective melanocortin MC4 receptor agonists reverse haemorrhagic shock and prevent multiple organ damage. Br J Pharmacol. 2007 Mar;150(5):595-603.

    [3]. Zhang Y, et al. Effects of RO27-3225 on neurogenesis, PDGFRβ+ cells and neuroinflammation after cerebral infarction. Int Immunopharmacol. 2020 Feb 11;81:106281.

Fluorescamine(Synonyms: 荧光胺 Ro 20-7234)

Fluorescamine;(Synonyms: 荧光胺; Ro 20-7234) 纯度: ge;98.0%

Fluorescamine( Ro 20-7234)是一个螺环化合物且本身无荧光性质,能与初级胺反应并形成荧光,因此被用来检测胺和肽。

Fluorescamineamp;;(Synonyms: 荧光胺; Ro 20-7234)

Fluorescamine Chemical Structure

CAS No. : 38183-12-9

规格 价格 是否有货 数量
10;mM;*;1 mL in DMSO ¥550 In-stock
10 mg ¥500 In-stock
50 mg ¥900 In-stock
100 mg ; 询价 ;
200 mg ; 询价 ;

* Please select Quantity before adding items.

Fluorescamine 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • FDA Approved amp; Pharmacopeial Drug Library

生物活性

Fluorescamine( Ro 20-7234) is a spiro compound that is not fluorescent itself, but reacts with primary amines to form highly fluorescent products. It hence has been used as a reagent for the detection of amines and peptides.

分子量

278.26

Formula

C17H10O4

CAS 号

38183-12-9

中文名称

荧光胺;萤咔明;弗路兰;荧胺

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4deg;C, protect from light

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (protect from light)

溶解性数据
In Vitro:;

DMSO : ≥ 33 mg/mL (118.59 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.5938 mL 17.9688 mL 35.9376 mL
5 mM 0.7188 mL 3.5938 mL 7.1875 mL
10 mM 0.3594 mL 1.7969 mL 3.5938 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂:;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.5 mg/mL (8.98 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (8.98 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂:;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (8.98 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (8.98 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂:;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.5 mg/mL (8.98 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (8.98 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。

Pall Cascada RO实验室反渗透纯水系统, PAL-CAXXXROM2

名称:Cascada RO实验室反渗透纯水系统

型号:PAL-CAXXXROM2

简介:Pall 颇尔 Cascada RO实验室反渗透纯水系统, PAL-CAXXXROM2

Pall 颇尔 Cascada RO实验室反渗透纯水系统, PAL-CAXXXROM2

 

产品介绍
利用Pall Cascada RO实验室反渗透纯水系统,轻松制备实验室级别用水
滤除效率高达99%- 利用Pall Cascada RO反渗透纯水系统,有机物、微生物和微粒物质
的有效滤除率高达99%。
操作简易- 体贴入微的用户控制界面,提供多种信息的状态,轻松的日常维护,从而
确保用户使用的便利性。
连续的水质监控-系统由微处理器控制,清楚地显示水质状况,并在异常情况下发出声
光报警,从而确保操作的一致性和可靠性。
数据的永久性记录-通过RS232端口,可进行数据采集,永久性地记录水质和系统相关
参数;对于实验室优良操作规范(GLP)的满足,这一点必不可少。
最大程度地提升系统效率- 采用最先进的RO(反渗透)技术,产水量极高,滤膜采用
新型复合材料,而非纤维素材质,从而确保性能表现的最优化。
随心所欲的安装方式- 人性化设计,可任意选择台上、台下或壁式安装

 

Pall 颇尔 Cascada RO实验室反渗透纯水系统, PAL-CAXXXROM2
Pall Cascada RO实验室反渗透纯水系统, PAL-CAXXXROM2
Pall Cascada RO实验室反渗透纯水系统, PAL-CAXXXROM2
 
Pall 颇尔 Cascada RO实验室反渗透纯水系统, PAL-CAXXXROM2

新品上市 | 干燥综合征A型抗原(Ro52)

Ro52蛋白又称为SSA52或TRIM21蛋白,具有TRIM蛋白家族的共同结构,即含有环指RING-finger、B-box、卷曲螺旋(coiled-coil)等3个主要的结构域,以及C端的B30.2结构。

新品上市 | 干燥综合征A型抗原(Ro52)

TRIM21蛋白与IgG Fc复合物结构

抗Ro52抗体广泛存在于自身免疫性疾病患者血清中。自身免疫性疾病患者血清中存在大量多种类的自身抗体,其中原发性干燥综合征、系统性红斑狼疮、系统性硬化病、原发性胆汁性肝硬化、风湿性关节炎、自身免疫性肝炎、先天性完全房室传导阻滞等疾病的抗Ro52抗体阳性率由5-63.2%不等,尤其是原发性干燥综合征患者Ro52抗体阳性率高达63.2%,因此Ro52又被称为干燥综合征抗原。此外,在先天性完全房室传导阻滞的胎儿母体血清中多数可检测到Ro52抗体,若能早期检测并及时人工干预,可有效降低胎儿先天疾病发生率。在自身免疫性肝病的检测中,抗Ro52也有可观的诊断效率。Granito等研究显示,在原发性胆汁性肝硬化患者中,抗Ro52抗体阳性率可达28%,结合胆红素等标志物可以对抗线粒体抗体阴性的自免肝予以诊断。

为了满足诊断市场的需求,博百欧新推出了一款重组抗原产品——Ro52抗原,该抗原由昆虫细胞Sf9表达,产品经检测与进口对照无异,欢迎广大客户测试和订购!

产品信息

产品编号:PB-R52

产品名称:Ro52 antigen

中文名称:Ro52抗原/干燥综合征A型抗原

原料来源:昆虫细胞Sf9

新品上市 | 干燥综合征A型抗原(Ro52)

博百欧作为国内体外诊断试剂核心原料自主研发和生产的高新技术企业,目前专注于自身免疫系统疾病抗原的研发和生产,品种涵盖系统性红斑狼疮,类风湿关节炎、干燥综合征、硬皮病、皮肌炎、血管炎、抗磷脂综合征、自免性肝病、自免性肾病、自免性甲状腺及胃肠道疾病等的诊断。现已完成了20多种天然自身免疫抗原产品和2种重组抗原的研发和批量生产(详见下表),产品具备高纯度、高稳定性、高活性、高特异性、低批间差等特点,经多方验证证明博百欧产品的质量与进口同类产品一致,部分抗原效价优于进口对照产品。今后博百欧还将陆续推出更多重组抗原产品,为自身免疫疾病领域诊断客户提供一站式产品服务,敬请期待!

抗原名称

货号

规格

天然抗原

Beta-2-Glycoprotein-1(Human)

PB-BTA

0.2mg / 1.0mg

Beta-2-Glycoprotein-1(Bovine)

PB-BB2

0.2mg / 1.0mg

BPI

PB-BPI

0.2mg / 1.0mg

Calprotectin

PB-CAL

0.2mg / 1.0mg

dsDNA

PB-DNA

0.2mg / 1.0mg

GBM

PB-GBM

0.2mg / 1.0mg

Histone

PB-HIS

0.2mg / 1.0mg

Histone(salt extraction)

PB-HST

0.2mg / 1.0mg

Histone H1

PB-HH1

0.2mg / 1.0mg

Histone H2A-H2B

PB-HH2

0.2mg / 1.0mg

Histone core Histone

PB-HCH

0.2mg / 1.0mg

Jo-1

PB-JO1

0.2mg / 1.0mg

Ku Antigen

PB-KUA

0.2mg / 1.0mg

La(SSB)

PB-SSB

0.2mg / 1.0mg

Lactoferrin

PB-LAC

0.2mg / 1.0mg

Mitochondrial Antigen

PB-MIT

0.2mg / 1.0mg

Myeloperoxidase (pANCA)-MPO

PB-MPO

0.2mg / 1.0mg

Nucleosome

PB-NUC

0.2mg / 1.0mg

Proteinase 3 (cANCA)-PR3

PB-PR3

0.2mg / 1.0mg

Rheumatoid factor antigen

(Human IgG Fc Fragment)

PB-RFA

0.2mg / 1.0mg

RNP-68K (Sm-free)

PB-R68

0.2mg / 1.0mg

RNP-Sm

PB-RSM

0.2mg / 1.0mg

Ro (SSA)

PB-SSA

0.2mg / 1.0mg

Scl-70

PB-SCL

0.2mg / 1.0mg

Sm

PB-SMI

0.2mg / 1.0mg

重组抗原

PCNA(大肠杆菌E.coli)

PB-PNA

0.2mg / 1.0mg

Ro52(昆虫细胞Sf9)

PB-R52

0.2mg / 1.0mg

上海金畔生物科技有限公司是武汉博百欧中国区一级代理商,为客户提供一站式体外诊断产品服务。如果您对上述产品感兴趣,欢迎随时拨打上海金畔生物科技有限公司客服热线021-50837765或者登陆网站www.jinpanbio.cn咨询订购。

参考文献:

[1] James L C , Keeble A H , Khan Z , et al. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function[J]. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104(15):6200-6205.

[2] 宋涛. 人自身抗原Ro52的酵母重组表达及其抗体检测斑点免疫金渗滤法的建立. 福建医科大学, 2011.

CDRC60201-Millipore密理博AFS8系统RO膜组件反渗透膜

产品型号CDRC60201

品       牌密理博

厂商性质代理商

产品简介
品牌 其他品牌 用途 反渗透
主体材质 其他 滤料类型 纤维
适用对象 有效过滤面积 -㎡
外形尺寸 –mm 设备重量 –kg

CDRC60201 Millipore密理博AFS8系统RO膜组件反渗透膜,反渗透膜可去除95%-99%的污染物,包括离子,微粒,细菌和有机分子(分子量> 200kDa)

详情介绍

CDRC60201 Millipore密理博AFS8系统RO膜组件反渗透膜

 

说明: 用于 Elix 5,RiOs 8和AFS 8 系统的 RO 膜

 商标名: Milli-RO 

 数量/包装: 1

 产品名称: RO 膜

CDRC60201 Millipore密理博AFS8系统RO膜组件反渗透膜

RiOs 5/8/16 水纯化系统介绍

直接生产 III 级实验室用水,产水流速可达 16L/hRiOs 系统以稳定的流速产生 III 级实验室用纯水 系统直接使用自来水做进水,将辅助纯化技术结合在一个紧凑的系统设计中,不仅操作方便、可靠,还允许以低操作成本对产水水质进行全面控制

 是一家经国家相关部门批准注册,主要经营生物实验仪器、耗材的高科技企业,代理GE旗下Whatman公司的定量滤纸,定性滤纸﹑玻璃纤维滤纸,石英纤维滤纸,色谱纸和离子交换纸,杂交纸,3MM层析纸过滤器有针头式滤器,多层针头式滤器,囊式过滤器.过滤漏斗萃取柱,萃取套管,层析填料,析纸,色谱柱,微孔过滤板和微孔收集板杂交膜、,微生物过滤装置,FTA卡,新生儿检测用纸(903纸) Nuclepore径迹蚀刻膜,Anodisc无机膜,Cyclopore PC聚碳酸酯膜,尼龙膜,PTFE, 聚四氟乙烯膜,ME25 混酯纤维素膜等所有whatman品牌产品以及PALL和密理博的相关产品。公司成立以来,经过公司各个部门的努力奋斗,与国内多家企业建立了良好的长期合作关系,在市场上树立了公司的良好信誉和形象。 我们拥有雄厚的实力、合理的价格和优良的服务,能够及时解决和满足客户的各方面的需求,热诚欢迎各界前来洽谈业务。

Ro 106-9920

Ro 106-9920;

Ro 106-9920 是一种有效的 NF-kappaB 抑制剂。Ro 106-9920 具有研究肿瘤和癌症疾病的潜力。

Ro 106-9920amp;;

Ro 106-9920 Chemical Structure

CAS No. : 62645-28-7

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

生物活性

Ro 106-9920 is a potent inhibitor of NF-kappaB. Ro 106-9920 has the potential for the research of tumor and cancer diseases[1].

IC50 Target

NF-kappaB[1]

分子量

245.26

Formula

C10H7N5OS

CAS 号

62645-28-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Malaver E, et al. NF-kappaB inhibitors impair platelet activation responses. J Thromb Haemost. 2009;7(8):1333-1343.